Whether this exchange keeps happening every month, or stops, is the variable this whole study turns on
Staff Sgt. Benjamin Stratton, U.S. Air Force
Illustrative: a general U.S. Air Force pharmacy scene from 2016, not from the cited study and not a specific GLP1 brand.
Stopping a GLP1 Drug Undoes Its Heart Protection, and Restarting Doesn't Fully Bring It Back
A study almost nobody outside cardiology circles noticed in March quietly answered one of the most practical questions a person on a GLP1 drug can ask. What happens to my heart if I stop? In a target trial emulation of 333,687 US veterans with type 2 diabetes, published March 18, 2026 in BMJ Medicine and given new attention when ScienceDaily republished it this September, researchers found that a GLP1 drug's cardiovascular protection builds slowly during continuous use, and mostly disappears within two years of stopping. Restarting helps. It does not fully bring the benefit back.
- In a target trial emulation of 333,687 US veterans with type 2 diabetes, staying on a GLP1 drug for three years cut major cardiovascular events, heart attack, stroke, and death, by 18 percent versus a sulfonylurea, about 4 fewer events per 100 people.
- Stopping erased most of that. Compared with continuous use, risk was 14 percent higher after one year off and 22 percent higher after two years off.
- People who took a GLP1 for less than 18 months before stopping showed no measurable heart benefit at all versus a sulfonylurea.
- Restarting after a gap helped, but not all the way back. Interrupting and resuming brought about a 12 percent average risk reduction, compared with 18 percent for staying on continuously.
What continuous use actually buys you
The study followed 132,551 GLP1 users and 201,136 sulfonylurea users for up to three years, all with type 2 diabetes. People who stayed on a GLP1 drug continuously for three years had an 18 percent lower risk of a major adverse cardiovascular event than people on a sulfonylurea, which works out to roughly 4 fewer events per 100 people. That protection was not immediate. It built up over time, which matters for what comes next, because a benefit that takes years to build can also take very little time to fade.
What stopping costs you
Twenty six percent of GLP1 users in the study stopped taking the drug, and about 23 percent had an interruption of 6 months or more before resuming. Compared with continuous use, stopping raised cardiovascular risk by 14 percent after one year off and by 22 percent after two years off. People who took a GLP1 for less than 18 months before stopping showed no significant benefit at all compared with sulfonylureas, meaning the protection never had time to establish itself. Restarting after an interruption did help, an average 12 percent risk reduction versus sulfonylureas, but that is well short of the 18 percent seen with continuous use. Even a 6 month gap cost an estimated 4 to 8 percent of the benefit before resuming.
Honest caveat
This is an observational study, not a randomized trial. A target trial emulation design reduces certain kinds of bias, but it cannot fully remove the fact that people who stop a GLP1 drug differ from people who continue, whether from side effects, cost, or a change in health status, and any of those could independently affect cardiovascular risk. The population is US veterans with type 2 diabetes, mostly older men, so the results may not carry over to people taking GLP1 drugs for weight loss alone, without diabetes. The comparator is a sulfonylurea, not a placebo, so these are relative numbers against another active diabetes drug. And the 4 percent figure some consumer outlets used for the 6 month interruption is the low end of a 4 to 8 percent range, not a single fixed number.
What this means for you
If you are thinking about taking a GLP1 drug for a few months to lose weight and then stopping, this study is a reason to talk to your prescriber before you do. The cardiovascular benefit these drugs offer does not appear to be something you bank once you have taken the drug for a while. It depends on staying on it, and it fades within roughly a year or two of stopping. This matters most for readers on compounded or telehealth GLP1 prescriptions, who are more exposed to cost driven or supply driven interruptions than someone with a stable pharmacy benefit. None of this is medical advice about whether you personally should start, continue, or stop a GLP1 drug. It is a reason to have that specific conversation, cardiovascular protection and continuity, with the person who prescribes it.
Primary sources
Common questions
What happens to my heart if I stop taking a GLP1 drug?
In this veterans study, cardiovascular risk was 14 percent higher after one year off a GLP1 drug and 22 percent higher after two years off, compared with staying on it continuously. People who used the drug for less than 18 months before stopping showed no measurable heart benefit at all versus a sulfonylurea.
If I restart my GLP1 drug after a break, do I get the same protection back?
Not fully. Restarting after an interruption brought about a 12 percent average risk reduction versus sulfonylureas, compared with 18 percent for people who never stopped. Even a 6 month gap cost roughly 4 to 8 percent of the benefit.
Does this apply to everyone taking a GLP1 drug, including for weight loss alone?
Not necessarily. The study followed 333,687 US veterans with type 2 diabetes, mostly older men, compared against a sulfonylurea rather than a placebo. The direction of the finding, that benefit fades after stopping, is consistent with other GLP1 rebound data, but this specific cardiovascular result has not been replicated in people taking these drugs for weight loss without diabetes.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.